Eli Lilly and Company (LLY) News
Follow Eli Lilly and Company (LLY) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 341 public stories across 80 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Eli Lilly Shares Rise 3.41% as Sales Outlook Improves, EPS Guidance Falls
Eli Lilly shares climbed 3.41% to $1,420.53 at 1:10 p.m. ET on October 30 as investors weighed higher sales expectations against a lower earnings outlook.
EARNINGS | Oct 30, 2026, 08:06 PM UTC
H
Eli Lilly and AbbVie shares hit records after earnings and outlook increases
Shares of Eli Lilly and AbbVie reached new highs Friday after both companies reported stronger-than-expected third-quarter earnings and raised their full-year 2026 outlooks. Lilly was up 3.5% at the time of writing.
EQUITY | Oct 30, 2026, 07:14 PM UTC
M
UBS Sees Eli Lilly Sustaining Obesity Growth
UBS said Eli Lilly's strong results and higher guidance support continued obesity growth.
EQUITY | Oct 30, 2026, 04:50 PM UTC
M
Nxera Pharma Reports Third-Quarter 2026 Results
Nxera Pharma published operational highlights and consolidated results for the third quarter of 2026.
EQUITY | Oct 30, 2026, 06:38 AM UTC
M
LLY Reports Fiscal Q3 Profit Growth of 49.56%
The report states fiscal third-quarter profit attributable to shareholders rose 49.56% year over year and basic EPS was reported.
EQUITY | Oct 30, 2026, 05:42 AM UTC
M
Eli Lilly raises full-year revenue outlook on drug demand
Eli Lilly raised its full-year revenue outlook, citing stronger demand for obesity and diabetes drugs.
EQUITY | Oct 30, 2026, 12:11 AM UTC
M
Lilly’s Foundayo Revenue Misses Wall Street Estimates by 19% in Q3
Eli Lilly reported $184 million in third-quarter revenue for its Foundayo weight-loss pill, 19% below Wall Street estimates. The once-daily pill is generally cheaper than injectable treatments.
EARNINGS | Oct 29, 2026, 07:21 PM UTC
M
Eli Lilly lifts revenue outlook as weight-loss shot demand soars
EARNINGS | Oct 29, 2026, 05:28 PM UTC
M
Eli Lilly Shares Hit Record High as Profit Beats and Revenue Forecast Rises
Sales of weight-loss injections helped Eli Lilly beat quarterly profit expectations and raise its full-year revenue forecast, according to the report.
EARNINGS | Oct 29, 2026, 04:20 PM UTC
M
Eli Lilly Expects Mounjaro to Maintain U.S. Leadership
Finance chief Lucas Montarce said Mounjaro’s U.S. revenue gained 41% to $5 billion in the latest quarter and pointed to strength outside the U.S.
EARNINGS | Oct 29, 2026, 03:55 PM UTC
M
Lilly Says Bridge Program Boosts GLP-1 Sales and Supports Raised Guidance
Eli Lilly says its U.S. Bridge program is boosting sales of its GLP-1 drugs and was a key driver of its raised full-year revenue guidance. The program started in July.
EARNINGS | Oct 29, 2026, 03:50 PM UTC
M
Eli Lilly Shares Jump 7% as Company Raises 2026 Outlook
Eli Lilly shares surged nearly 7% on Thursday after the company raised its 2026 outlook.
EARNINGS | Oct 29, 2026, 03:44 PM UTC
M
Petrobras Reports Record Third-Quarter Production; Ambev Profit Falls 10%
The headline reports record production at Petrobras in the third quarter and a 10% decline in Ambev's profit.
EQUITY | Oct 29, 2026, 03:43 PM UTC
M
Lilly Raises Sales Outlook by $5.5 Billion, Cuts EPS Forecast
Eli Lilly reported third-quarter non-GAAP EPS of $7.48 versus analysts’ consensus of $5.68 and revenue of $24.4 billion versus $22.58 billion. Revenue rose 39%, with volume up 53% and realized prices down 15%.
EARNINGS | Oct 29, 2026, 03:41 PM UTC
M
Eli Lilly Raises 2026 Sales Outlook on Strong Mounjaro, Zepbound Demand
Eli Lilly raised its full-year sales outlook after third-quarter results topped expectations. Revenue rose 38.6% year over year to $24.4 billion, beating consensus by $1.78 billion.
EARNINGS | Oct 29, 2026, 03:13 PM UTC
M
Eli Lilly Reports Quarterly Results Above Wall Street Estimates
Eli Lilly reported EPS of $7.48, above the $6.26 estimate cited in the report. Sales of its weight-loss drugs continue to accelerate, the report says.
EQUITY | Oct 29, 2026, 02:26 PM UTC
M
Eli Lilly Raises Revenue Forecast as Shares Surge
Higher revenue guidance offsets weaker-than-expected results for its weight-loss injections and Foundayo.
EARNINGS | Oct 29, 2026, 02:13 PM UTC
M
Eli Lilly Raises Revenue Outlook as Weight-Loss Shots Offset Foundayo Sales Miss
Eli Lilly raised its revenue outlook, with weight-loss shot sales offsetting a Foundayo sales miss; its shares jumped.
EARNINGS | Oct 29, 2026, 02:12 PM UTC
M
Eli Lilly Shares Rise 8.2% After Revenue Outlook Lift
Eli Lilly raised its annual revenue outlook as shares rose 8.2%.
EQUITY | Oct 29, 2026, 01:40 PM UTC
M
Eli Lilly Raises FY 2026 Revenue Outlook; Shares Hit Record High
Eli Lilly raised its full-year 2026 revenue outlook after better-than-expected third-quarter earnings. Shares climbed 5.2% in premarket trading to all-time highs.
EARNINGS | Oct 29, 2026, 12:44 PM UTC
M
US Equity Futures Edge Lower Before the Bell
US equity futures were edging lower before the bell Thursday.
EQUITY | Oct 29, 2026, 12:12 PM UTC
M
Eli Lilly Reports Q3 Revenue of $24.4 Billion, Raises 2026 Guidance
Third-quarter revenue rose 39% to $24.4 billion, above analyst estimates of $22.58 billion. Adjusted EPS was $7.48 versus $5.68 expected. Lilly raised full-year revenue guidance to $91 billion-$92 billion from $85 billio
EQUITY | Oct 29, 2026, 11:55 AM UTC
M
US Equity Futures Trade Lower Before Inflation Report, Amazon Earnings
US equity futures were lower ahead of a key inflation report and Amazon earnings.
EQUITY | Oct 29, 2026, 11:50 AM UTC
M
Eli Lilly Reports Q3 2026 Net Income and Revenue Growth
Eli Lilly reported Q3 2026 net income and revenue growth.
EQUITY | Oct 29, 2026, 11:22 AM UTC
M
Eli Lilly reports $24.4B in third-quarter revenue
EQUITY | Oct 29, 2026, 11:13 AM UTC
M
Lilly Reports Third-Quarter 2026 Results, Raises Full-Year Guidance
Eli Lilly reported third-quarter 2026 financial results and updated its full-year 2026 guidance.
EQUITY | Oct 29, 2026, 11:11 AM UTC
M
Eli Lilly Raises Revenue Forecast, Cuts Profit Estimate
The company cited weight-loss drug sales for the higher revenue outlook and expenses from agreements for the lower profit estimate.
EARNINGS | Oct 29, 2026, 11:02 AM UTC
M
Eli Lilly shares rise 2.2% premarket ahead of results
EQUITY | Oct 29, 2026, 10:56 AM UTC
M
Eli Lilly Sees FY Revenue at $91B-$92B
EARNINGS | Oct 29, 2026, 10:52 AM UTC
M
Eli Lilly 3Q R&D Expenses Rise 23% to $4.2B
Research and development expenses were 17% of revenue in the third quarter.
EQUITY | Oct 29, 2026, 10:49 AM UTC
M
Eli Lilly reports third-quarter adjusted EPS of $7.48
EARNINGS | Oct 29, 2026, 10:49 AM UTC
M
Lilly Q3 Revenue Included About $900 Million in Benefits
The benefits mainly included $410 million from Jardiance milestones and favorable adjustments to rebate and discount estimates.
EQUITY | Oct 29, 2026, 10:49 AM UTC
M
Eli Lilly reports Mounjaro revenue of $10.7B in 3Q
EARNINGS | Oct 29, 2026, 10:48 AM UTC
M
Eli Lilly Reports Zepbound Revenue of $5.35B in 3Q
EARNINGS | Oct 29, 2026, 10:48 AM UTC
M
Lilly Lowers FY Adjusted EPS Outlook to $35-$36
Lilly's FY adjusted EPS outlook is $35 to $36, versus its prior forecast of $35.5 to $36.5.
EARNINGS | Oct 29, 2026, 10:48 AM UTC
M
Eli Lilly 3Q U.S. Volume Rose 41%, Realized Prices Fell 7%
EQUITY | Oct 29, 2026, 10:48 AM UTC
H
$LLY Eli Lilly Q3 Earnings
Adj. EPS $7.48, est. $5.59 Rev. $24.40B, est. $22.52B Mounjaro rev. $10.7B, est. $9.95B Zepbound rev. $5.35B, est. $5.01B Foundayo rev. $184M, est. $231.2M Acquired IPR&D charges $4.57/share Sees FY rev. $91B to $92B, sa
EARNINGS | Oct 29, 2026, 10:48 AM UTC
M
Eli Lilly 3Q U.S. Revenue Rises 34% to $15.1B
EARNINGS | Oct 29, 2026, 10:48 AM UTC
M
Eli Lilly reports third-quarter net income of $6.45 billion
EARNINGS | Oct 29, 2026, 10:45 AM UTC
L
Eli Lilly reports third-quarter EPS of $7.22
EARNINGS | Oct 29, 2026, 10:45 AM UTC
M
Eli Lilly Sees FY Adjusted EPS of $35.00-$36.00
EARNINGS | Oct 29, 2026, 10:45 AM UTC
M
Eli Lilly Q3 Earnings Preview: Analysts Expect $22.61 Billion Revenue
Eli Lilly is expected to report third-quarter revenue of about $22.61 billion on Oct. 29, up roughly 28% year over year. Analysts forecast adjusted earnings of $6.25 per share; some tracking models show about $9.81, depe
EQUITY | Oct 28, 2026, 07:53 PM UTC
M
Eli Lilly Shares Rise After Retatrutide Trial Results
Shares rose 1.21% to $1,297.37 at 11:24 a.m. ET after Reuters reported that experimental retatrutide beat Ozempic on weight loss and blood sugar control.
EQUITY | Oct 28, 2026, 05:46 PM UTC
M
Lilly’s Retatrutide Outperforms Ozempic on Weight Loss and Blood Sugar Control in Phase 2 Trial
Phase 2 trial results showed Lilly’s retatrutide outperformed Ozempic on weight loss and blood sugar control.
EQUITY | Oct 28, 2026, 04:08 PM UTC
L
Lilly's Retatrutide Outperforms Ozempic on Weight Loss and Blood Sugar Control in Trial
A trial found Lilly's retatrutide outperformed Ozempic on weight loss and blood sugar control.
EQUITY | Oct 28, 2026, 02:23 PM UTC
M
Lilly Says Retatrutide More Than Doubles Ozempic Weight Loss in Trial
Eli Lilly said its experimental diabetes and obesity drug retatrutide delivered more than double the weight loss of Novo Nordisk’s Ozempic in a head-to-head trial.
EQUITY | Oct 28, 2026, 12:36 PM UTC
M
Eli Lilly Q3'26 Earnings Preview Lists 5.68 EPS Estimate
Eli Lilly is scheduled to report Q3'26 results on October 29 before the market opens. Revenue is estimated at 22.58 billion USD, with EPS at 5.68 USD.
EQUITY | Oct 28, 2026, 11:00 AM UTC
M
Lilly Retatrutide Shows Greater A1C Reduction in Head-to-Head Trial
In adults with type 2 diabetes, retatrutide lowered A1C by an average of 2.2% versus 1.8% with Ozempic. Lilly said retatrutide also produced more than double the weight loss of Ozempic’s highest approved dose.
EQUITY | Oct 28, 2026, 10:49 AM UTC
M
Lilly’s Retatrutide Lowers A1C 2.2% at 80 Weeks in Type 2 Diabetes
Retatrutide lowered A1C by an average 2.2% at 80 weeks in adults with type 2 diabetes, versus 1.8% with Ozempic 2 mg.
EQUITY | Oct 28, 2026, 10:45 AM UTC
M
Lilly Retatrutide Cuts Body Weight by Up to 20.9% at 80 Weeks
Retatrutide 9 mg and 12 mg cut body weight by 19.5% and 20.9%, respectively, at 80 weeks, versus 9.4% with Ozempic 2 mg.
EQUITY | Oct 28, 2026, 10:45 AM UTC
M
Hengrui Pharma Reports 88.9% Rise in Third-Quarter Profit
Hengrui Pharma reported an 88.9% rise in third-quarter 2026 profit, attributed in the headline to licensing deals.
EQUITY | Oct 27, 2026, 09:53 AM UTC
M
Hengrui Pharma registra alta de 88,9% no lucro do terceiro trimestre
A empresa atribuiu o aumento do lucro a acordos de licenciamento.
EARNINGS | Oct 27, 2026, 09:53 AM UTC
M
Cipla Misses Profit Targets as US Market Weakness Weighs
Cipla failed to meet its profit targets, citing weakness in the US market; its shares declined.
EARNINGS | Oct 27, 2026, 09:02 AM UTC
L
Cipla misses earnings expectations as shares fall
Cipla missed earnings expectations amid weak performance in the U.S. market, and its shares fell.
EARNINGS | Oct 27, 2026, 09:01 AM UTC
L
Novo Nordisk Reportedly Loses US Ruling to Block Eli Lilly Drug Ads
Novo Nordisk failed to convince a U.S. judge to block Eli Lilly weight-loss drug ads.
REGULATION | Oct 27, 2026, 08:53 AM UTC
L
US Judge Denies Bid to Block Eli Lilly Weight-Loss Drug Ads
A US judge denied a request to block advertising for Eli Lilly weight-loss drugs and ruled against Novo Nordisk.
REGULATION | Oct 26, 2026, 10:27 PM UTC
L
US Judge Rejects Lilly Request to Bar Novo Nordisk Weight-Loss Drug Ads
A US judge rejected Eli Lilly’s request to prohibit advertising for Novo Nordisk weight-loss drugs, ruling against Novo Nordisk. The correction notice says paragraph 10 and a third bullet were revised but provides no fur
REGULATION | Oct 26, 2026, 10:26 PM UTC
M
US Judge Rejects Lilly Request to Bar Novo Weight-Loss Drug Ads
A US judge rejected Eli Lilly's request to bar advertising for Novo Nordisk's weight-loss drugs and ruled against Novo Nordisk.
REGULATION | Oct 26, 2026, 09:46 PM UTC
L
US Judge Rejects Bid to Block Lilly Weight-Loss Drug Ads
A US judge rejected a request to block advertising for Eli Lilly’s weight-loss drug. The wire headline does not identify the drug or provide further details.
REGULATION | Oct 26, 2026, 09:46 PM UTC
M
US Judge Lets Eli Lilly Continue Weight-Loss Drug Ads
A US judge ruled against Novo Nordisk, allowing Eli Lilly to continue advertising its weight-loss drugs.
REGULATION | Oct 26, 2026, 07:59 PM UTC